March 12, 2020 / 12:18 PM / 17 days ago

BRIEF-Boehringer Ingelheim And Eli Lilly And Company: FDA Grants Fast Track Designation To Empagliflozin

March 12 (Reuters) - BOEHRINGER INGELHEIM AND ELI LILLY AND COMPANY:

* U.S. FDA GRANTS FAST TRACK DESIGNATION TO EMPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

* BOEHRINGER INGELHEIM AND ELI LILLY AND COMPANY - FDA GRANTS FAST TRACK DESIGNATION FOR INVESTIGATION OF EMPAGLIFLOZIN TO REDUCE RISK OF KIDNEY DISEASE PROGRESSION AND CARDIOVASCULAR DEATH IN ADULTS WITH CHRONIC KIDNEY DISEASE Source text for Eikon: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below